Clinical trial · Observational
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
A Multicentre, Retrospective, Non-interventional Review of Electronic Prescribing Records of Any Second-line (2L) Patients and Chart Notes of 2L Cabozantinib Patients, Investigating the Treatment Sequence Pathway Following a First-line, Immuno-oncology Checkpoint Inhibitor (1L IO) Containing Combination Therapy in Patients With Advanced Renal Cell Carcinoma (aRCC) (CARINA)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination therapy and progressed to a 2L treatment with particular focus to understanding where cabozantinib is prescribed after 1L IO containing combination therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Renal Cell Carcinoma (aRCC) | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- label
- Cohort 2
Primary outcomes (2)
- measure
- Description of the treatment sequence pathway from 1L up to 2L for patients with aRCC
- timeFrame
- From start of treatment to last hospital follow-up or date of death whichever occurs first assessed during data collection period (from 15th of January 2015 until September 2022)
- description
- To be described for patients with aRCC receiving 2L treatment following a 1L IO containing combination therapy.
- measure
- Description of the treatment sequence pathway from 1L up to the 2L for cabozantinib patients with aRCC
- timeFrame
- From start of treatment to last hospital follow-up or date of death whichever occurs first assessed during data collection period (from 15th of January 2015 until September 2022)
- description
- To be described for patients with aRCC receiving 2L treatment and subsequent lines of treatment following a 1L IO containing combination therapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of aRCC. * Patients aged ≥18 years at aRCC diagnosis treated with a 1L IO containing combination therapy who have progressed to a 2L treatment. Exclusion Criteria: * Patient's hospital medical records are unavailable for review; * Patients have started a 2L treatment as part of a Renal Carcinoma Treatment (RCT).
References
Publications (1)
- DERIVEDNathan P, Venugopal B, Ali J, Allison J, Ceruso M, Charnley N, Griffiths R, Michael A, Moore K, Perrot V, Prendergast A, Sharma A, Szabados B, Larkin J. Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results. Clin Genitourin Cancer. 2024 Oct;22(5):102141. doi: 10.1016/j.clgc.2024.102141. Epub 2024 Jun 26. PMID 39107157